Gilead to launch generic versions of Epclusa and Harvoni

|By:, SA News Editor

Gilead Sciences (NASDAQ:GILD) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S.

The drugs, priced at $24,000 list to more closely match what the government and health insurers pay, will be available in January 2019. The company says that Medicare Part D patients could save up to $2,500 in out-of-pocket costs per course of therapy.

Related tickers: (NYSE:ABBV)(NYSE:PFE)(NYSE:GSK)(OTCPK:SGIOF)(NYSE:MRK)(OTCPK:THERF)(NYSE:BMY)(NYSE:JNJ)

Subscribe for full text news in your inbox